Customize AHL7 Antibody

Description

Terminology Clarification

The term "AHL7" does not correspond to any known antibody, antigen, or biomedical entity in peer-reviewed literature, clinical trial registries, or standardized antibody nomenclature systems (e.g., WHO’s International Nonproprietary Names for antibodies) .

Potential Misinterpretations:
- HL7: Health Level Seven International (HL7) is a framework for healthcare data exchange standards, unrelated to antibodies .
- AHL7 vs. HLA/IL-7: No linkage exists between "AHL7" and established immune system components like HLA (human leukocyte antigen) or IL-7 (interleukin-7).

Analysis of Search Results

The provided sources extensively cover antibody structures (e.g., IgG, IgA), bispecific antibodies (e.g., 10E8.4/iMab), and monoclonal antibodies (e.g., W6/32, VRC07-523LS) but lack any reference to "AHL7" .

Key Antibody Classes and Functions

Antibody Class	Structure	Function	Example Therapeutics
IgG	Y-shaped, 2 heavy + 2 light chains	Neutralizes pathogens, activates complement	Trastuzumab (HER2+)
IgA	Dimer, hinge region	Mucosal immunity, antigen aggregation	N/A
Bispecific	Dual antigen-binding sites	Targets multiple epitopes (e.g., HIV, cancer)	Glofitamab (CD20×CD3)

Research Gaps and Recommendations

If "AHL7 Antibody" refers to a novel or proprietary compound, additional context is required to validate its existence. Potential steps for clarification:

Verify Spelling/Nomenclature: Confirm if the term is a typographical error (e.g., "anti-HL7" or "AHL-7").
Patent Databases: Search the USPTO or WIPO for unpublished or proprietary antibody designs.
Contact Developers: Reach out to institutions like the Aaron Diamond AIDS Research Center or ADC Therapeutics, which specialize in engineered antibodies .

Product Specs

Buffer

Preservative: 0.03% ProClin 300; Constituents: 50% Glycerol, 0.01M PBS, pH 7.4

Form

Liquid

Lead Time

14-16 weeks lead time (made-to-order)

Synonyms

AHL7 antibody; At4g00200 antibody; F6N15.24AT-hook motif nuclear-localized protein 7 antibody

Target Names

AHL7

Uniprot No.

Q4V3E0

Target Background

Function

This antibody targets a transcription factor that exhibits specific binding affinity for AT-rich DNA sequences associated with nuclear matrix attachment regions (MARs).

Database Links

KEGG: ath:AT4G00200

STRING: 3702.AT4G00200.1

UniGene: At.34588

Subcellular Location

Nucleus.

Q&A

The following FAQs address key research considerations for working with AHL7 antibodies in academic settings, emphasizing experimental rigor, methodological approaches, and data interpretation challenges. The content integrates insights from antibody development frameworks and clinical data standards.

Advanced Research Challenges

How to resolve contradictory results between AHL7 antibody performance in IHC vs. flow cytometry?

Investigate epitope accessibility differences:
- IHC detects fixed, linear epitopes, while flow cytometry often targets native conformational epitopes .
- Perform antigen retrieval optimization (e.g., citrate buffer pH 6.0 vs. Tris-EDTA pH 9.0) .
Quantify antibody affinity differences using surface plasmon resonance (SPR) with recombinant antigens .

What statistical approaches optimize AHL7 antibody titration in multiplex assays?

Apply Design of Experiments (DOE) principles:
- Use fractional factorial designs to evaluate interaction effects between antibody concentration, incubation time, and temperature .
- Model responses (e.g., signal-to-noise ratio, cross-reactivity) using MODDE software for robust parameter optimization .

Data Interpretation & Standardization

How to harmonize AHL7 antibody data across research groups?

Adopt HL7 Specimen DAM standards for metadata reporting:
- Document clone name, lot number, and validation protocols using structured fields .
- Use FHIR resources to link antibody performance data with experimental conditions .

What bioinformatics tools handle batch effects in AHL7 antibody-derived datasets?

Implement ComBat or SVA algorithms for batch correction in gene expression studies .
Validate correction efficacy through PCA clustering analysis of technical replicates .

Methodological Optimization

Which quality metrics define AHL7 antibody stability under long-term storage?

Parameter	Assessment Method	Acceptance Criteria
Aggregation propensity	Dynamic light scattering (DLS)	PDI < 0.2 across 3 freeze-thaw cycles
Epitope integrity	Competitive ELISA	<15% signal reduction vs. fresh aliquot

How to design longitudinal studies using AHL7 antibodies with evolving epitope targets?

Establish time-resolved epitope mapping protocols:
- Perform hydrogen-deuterium exchange mass spectrometry (HDX-MS) quarterly to detect structural drift .
- Maintain frozen aliquots of original antigen stocks as reference comparators .

Quick Inquiry

Personal Email Detected

Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *

Name*

Email*

Phone

Country

Source

Quantity&Size*

Product Name

Message

AHL7 Antibody